No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

3 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis

NCT00604955Phase 4Completed2000 enrolled

Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children

NCT01032187Phase 4Completed101 enrolled

Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh

NCT03311607Phase 4Completed280 enrolled

View all 3 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

New WHO guidelines for treating rhodesiense human African trypanosomiasis: expanded indications for fexinidazole and pentamidine.

Lindner Andreas K, Lejon Veerle, Barrett Michael P et al. · Lancet Infect Dis · 2025

PMID: 39389073Meta-Analysis

Efficacy and safety of pentamidine isethionate for tegumentary and visceral human leishmaniasis: a systematic review.

Piccica Matteo, Lagi Filippo, Bartoloni Alessandro et al. · J Travel Med · 2021

PMID: 33890115Meta-Analysis

Evaluation of itraconazole monotherapy versus its combination with a single dose of pentamidine for treating cutaneous leishmaniasis caused by Leishmania (Viannia) guyanensis in Amazonas state, western Brazilian Amazon.

Cavalcante Melissa de Sousa Melo, da Silva Lara Isabelli Oliveira, Ortiz Jessica Vanina et al. · Trop Med Int Health · 2025

PMID: 40642881RCT

Intralesional Pentamidine: A Novel Therapy for Single Lesions of Bolivian Cutaneous Leishmaniasis.

Soto Jaime, Paz David, Rivero Daniela et al. · Am J Trop Med Hyg · 2016

PMID: 26903605RCTFull text (PMC)

Randomized single-blinded non-inferiority trial of 7 mg/kg pentamidine isethionate versus 4 mg/kg pentamidine isethionate for cutaneous leishmaniaisis in Suriname.

Hu Ricardo V P F, Straetemans Masja, Kent Alida D et al. · PLoS Negl Trop Dis · 2015

PMID: 25793773RCTFull text (PMC)

Comparison between the Outcomes of Pentamidine and Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia in Non-HIV Patients: A Nationwide Japanese Retrospective Cohort Study.

Taniguchi Jumpei, Aso Shotaro, Matsui Hiroki et al. · Intern Med · 2025

PMID: 39756875ObservationalFull text (PMC)

Comparative in vitro transportation of pentamidine across the blood-brain barrier using polycaprolactone nanoparticles and phosphatidylcholine liposomes.

Omarch Geofrey, Kippie Yunus, Mentor Shireen et al. · Artif Cells Nanomed Biotechnol · 2019

PMID: 31007068Observational

In Vitro and In Vivo Comparison of Two Nebulizers Used for Inhaled Pentamidine Delivery.

Audag Nicolas, Liistro Giuseppe, Van der Linden Dimitri et al. · Arch Bronconeumol · 2017

PMID: 28583257Observational

Monitoring the response of patients with cutaneous leishmaniasis to treatment with pentamidine isethionate by quantitative real-time PCR, and identification of Leishmania parasites not responding to therapy.

Mans D R A, Kent A D, Hu R V et al. · Clin Exp Dermatol · 2016

PMID: 26648589Observational

In vivo SPECT imaging of [¹²³I]-labeled pentamidine pro-drugs for the treatment of human African trypanosomiasis, pharmacokinetics, and bioavailability studies in rats.

Cohrs Björn, Zhao Yi, Lützen Ulf et al. · Int J Pharm · 2014

PMID: 25455769Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Pentamidine (substance)
SNOMED CT: 372699006
UMLS CUI: C0030863
RxNorm CUI: 7994

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.